Elicio Therapeutics (ELTX) EBIAT (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of EBIAT data on file, last reported at -$11.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBIAT fell 5.48% year-over-year to -$11.8 million; the trailing twelve-month figure through Mar 2026 stood at -$40.2 million (up 21.64% YoY), and the FY2025 full-year result was -$39.6 million, up 23.75% from the prior year.
• EBIAT for Q1 2026 stood at -$11.8 million, down from -$7.7 million in the prior quarter.
• Across five years, EBIAT topped out at -$6.7 million in Q4 2022 and bottomed at -$18.8 million in Q3 2024.
• The 5-year median for EBIAT is -$8.9 million (2023), against an average of -$9.8 million.
• Peak annual rise in EBIAT reached 80.76% in 2022, while the deepest fall reached 144.67% in 2022.
• A 5-year view of EBIAT shows it stood at -$6.7 million in 2022, then slumped by 34.55% to -$8.9 million in 2023, then sank by 56.49% to -$14.0 million in 2024, then surged by 44.89% to -$7.7 million in 2025, then sank by 53.19% to -$11.8 million in 2026.
• The last three EBIAT figures came in at -$11.8 million (Q1 2026), -$7.7 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.

Peer Comparison